CAMK2N1 is a potent calcium/calmodulin-dependent protein kinase II (CAMK2) inhibitor with pleiotropic roles in cardiovascular, metabolic, and cancer-related pathways. Functionally, CAMK2N1 regulates blood pressure and left ventricular mass through CAMK2 inhibition in cardiovascular tissues 1. In the kidney, CAMK2N1 modulates sodium handling by suppressing CUL3-mediated WNK4 degradation; CAMK2N1 deletion increases CUL3 neddylation, reducing NCC phosphorylation and lowering systemic blood pressure 2. Beyond CAMK2 inhibition, CAMK2N1 reduces insulin sensitivity and promotes adiposity through independent mechanisms 1. CAMK2N1 functions as a tumor suppressor across multiple cancer types. In hepatocellular carcinoma, it suppresses E2F1-mediated cell-cycle progression and induces P27/KIP1 expression 3. In colorectal carcinoma, CAMK2N1 inhibits Wnt/β-catenin signaling, reducing proliferation and metastasis 4. In prostate cancer, downregulation correlates with poor prognosis and endocrine resistance; CAMK2N1 forms a negative feedback loop with androgen receptor signaling 5. In prostate cancer, reduced CAMK2N1 expression downregulates IGF-1, ErbB2, and VEGF-mediated pathways 6. PRMT5-mediated histone methylation represses CAMK2N1 transcription, promoting prostate cancer progression 7. CAMK2N1 is enriched in specific prefrontal projections involved in temporal cognition 8.